Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BudapestICIVasc
2025-523620-44-02Phase 4Authorised
- Sponsor
- Semmelweis University
- Start
- Jan 2026
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, single-arm trial of durvalumab, ipilimumab, nivolumab, atezolizumab and pembrolizumab in non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), renal cell carcinoma (RCC) and 3 more, sponsored by Semmelweis University. Planned start Jan 2026; status: authorised.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)renal cell carcinoma (RCC)head and neck cancer (HNC)bladder cancer
Beyond the preview
Go deeper on 2025-523620-44-02.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523620-44-02.